奥沙利铂：分子靶向治疗时代的回顾。
Oxaliplatin: a review in the era of molecularly targeted therapy.
机构信息
McGill University Departments of Oncology and Medicine, Montreal, QC.
出版信息
Curr Oncol. 2011 Jan;18(1):18-25. doi: 10.3747/co.v18i1.708.
Abstract
OBJECTIVE
To review preclinical and clinical data for oxaliplatin in the current context of molecularly targeted therapy.
METHODS OF STUDY SELECTION
We searched the PubMed and PubChem databases by combining the search terms "oxaliplatin" or "platinum" or both, with "clinical trials," "pharmacokinetics," and "pharmacodynamics."
DATA EXTRACTION AND SYNTHESIS
Oxaliplatin has a complicated pharmacokinetic profile, with activity against digestive cancers in particular. It has several mechanisms of action, but cancer cells can develop resistance. Real or potential synergism has been observed when oxaliplatin is combined with other cytotoxic agents or molecularly targeted agents. Peripheral neuropathy is a prominent toxic effect.
CONCLUSIONS
Oxaliplatin lends itself to further clinical research in combination with molecularly targeted therapy.
摘要
目的
在分子靶向治疗的背景下，综述奥沙利铂的临床前和临床数据。
研究选择方法
我们通过将搜索词“奥沙利铂”或“铂”或两者与“临床试验”、“药代动力学”和“药效学”相结合，在 PubMed 和 PubChem 数据库中进行搜索。
数据提取和综合
奥沙利铂具有复杂的药代动力学特征，对消化道癌症尤其有效。它有几种作用机制，但癌细胞可以产生耐药性。当奥沙利铂与其他细胞毒性药物或分子靶向药物联合使用时，观察到了真正或潜在的协同作用。周围神经病变是一种突出的毒性作用。
结论
奥沙利铂适合与分子靶向治疗进一步进行临床研究。
相似文献
1
Oxaliplatin: a review in the era of molecularly targeted therapy.奥沙利铂：分子靶向治疗时代的回顾。
Curr Oncol. 2011 Jan;18(1):18-25. doi: 10.3747/co.v18i1.708.
2
Oxaliplatin: pharmacokinetics and chronopharmacological aspects.奥沙利铂：药代动力学与时辰药理学方面
Clin Pharmacokinet. 2000 Jan;38(1):1-21. doi: 10.2165/00003088-200038010-00001.
3
Oxaliplatin. A review of its pharmacological properties and clinical efficacy in metastatic colorectal cancer and its potential in other malignancies.奥沙利铂。对其在转移性结直肠癌中的药理特性、临床疗效及其在其他恶性肿瘤中的潜力的综述。
Drugs. 2000 Oct;60(4):895-924. doi: 10.2165/00003495-200060040-00005.
4
Oxaliplatin: a review of preclinical and clinical studies.奥沙利铂：临床前和临床研究综述
Ann Oncol. 1998 Oct;9(10):1053-71. doi: 10.1023/a:1008213732429.
5
Pharmacokinetics and safety profile of oxaliplatin.奥沙利铂的药代动力学及安全性概况
Semin Oncol. 1998 Apr;25(2 Suppl 5):13-22.
6
Cellular and molecular pharmacology of oxaliplatin.奥沙利铂的细胞与分子药理学
Mol Cancer Ther. 2002 Jan;1(3):227-35.
7
Different infusion durations for preventing platinum-induced hearing loss in children with cancer.预防癌症患儿铂类药物所致听力损失的不同输注持续时间
Cochrane Database Syst Rev. 2016 Aug 8(8):CD010885. doi: 10.1002/14651858.CD010885.pub3.
8
Oxaliplatin in first-line therapy for advanced non-small-cell lung cancer.奥沙利铂用于一线治疗晚期非小细胞肺癌。
Clin Lung Cancer. 2010 Jan;11(1):18-24. doi: 10.3816/CLC.2010.n.003.
9
[Oxaliplatin: the first DACH platinum in clinical practice].[奥沙利铂：临床实践中的首个德国-奥地利-瑞士铂类药物]
Bull Cancer. 1997 Jun;84(6):665-73.
10
Combination of oxaliplatin plus irinotecan in patients with gastrointestinal tumors: results of two independent phase I studies with pharmacokinetics.奥沙利铂联合伊立替康治疗胃肠道肿瘤患者：两项独立的I期药代动力学研究结果
J Clin Oncol. 1999 Jun;17(6):1751-9. doi: 10.1200/JCO.1999.17.6.1751.
引用本文的文献
1
Cilastatin Modulates DPEP1- and IQGAP1-Associated Neuro-Glio-Vascular Inflammation in Oxaliplatin-Induced Peripheral Neurotoxicity.西司他丁调节奥沙利铂诱导的周围神经毒性中与二肽基肽酶1（DPEP1）和IQGAP1相关的神经-胶质-血管炎症。
Cells. 2025 Aug 20;14(16):1294. doi: 10.3390/cells14161294.
2
Targeting cytokine and chemokine signaling pathways for enhancing chemo-sensitivity in colorectal cancer.靶向细胞因子和趋化因子信号通路以增强结直肠癌的化疗敏感性
Cell Commun Signal. 2025 Aug 12;23(1):369. doi: 10.1186/s12964-025-02235-7.
3
Transcriptomic Landscape of Paclitaxel-Induced Multidrug Resistance in 3D Cultures of Colon Cancer Cell Line DLD1.结肠癌细胞系DLD1三维培养中紫杉醇诱导的多药耐药的转录组图谱
Int J Mol Sci. 2025 Jul 9;26(14):6580. doi: 10.3390/ijms26146580.
4
Advances in platinum-based cancer therapy: overcoming platinum resistance through rational combinatorial strategies.铂类癌症治疗的进展：通过合理的联合策略克服铂耐药性
Med Oncol. 2025 Jun 16;42(7):262. doi: 10.1007/s12032-025-02812-3.
5
HGF/c-Met Axis-Targeted Nanotherapy via GSH-Responsive Polymer Platforms Suppresses Uveal Melanoma Metastasis.通过谷胱甘肽响应性聚合物平台进行的HGF/c-Met轴靶向纳米治疗可抑制葡萄膜黑色素瘤转移。
Adv Healthc Mater. 2025 Jun;14(15):e2405056. doi: 10.1002/adhm.202405056. Epub 2025 May 8.
6
Analgesic and neuroprotective effect of a lipid transfer protein isolated from Morinda citrifolia L. (noni) seeds on oxaliplatin-induced peripheral sensory neuropathy in mice.从海巴戟（诺丽）种子中分离出的一种脂质转移蛋白对小鼠奥沙利铂诱导的周围感觉神经病变的镇痛和神经保护作用。
Naunyn Schmiedebergs Arch Pharmacol. 2025 Apr 30. doi: 10.1007/s00210-025-04216-6.
7
Subcellular localisation and identification of single atoms using quantitative scanning transmission electron microscopy.利用定量扫描透射电子显微镜进行单原子的亚细胞定位与识别。
J Microsc. 2025 Jul;299(1):36-48. doi: 10.1111/jmi.13410. Epub 2025 Apr 15.
8
Metabolic crossroads: unravelling immune cell dynamics in gastrointestinal cancer drug resistance.代谢交叉点：解析胃肠道癌耐药中免疫细胞的动态变化
Cancer Drug Resist. 2025 Feb 8;8:7. doi: 10.20517/cdr.2024.164. eCollection 2025.
9
Patient-derived tumor xenograft animal model of gastric cancer in precision chemotherapy.用于精准化疗的胃癌患者来源肿瘤异种移植动物模型
Naunyn Schmiedebergs Arch Pharmacol. 2025 Feb 19. doi: 10.1007/s00210-025-03903-8.
10
Predicting patient outcomes with gene-expression biomarkers from colorectal cancer organoids and cell lines.利用结直肠癌类器官和细胞系中的基因表达生物标志物预测患者预后。
Front Mol Biosci. 2025 Jan 15;12:1531175. doi: 10.3389/fmolb.2025.1531175. eCollection 2025.
本文引用的文献
1
Treatment-related toxicity and supportive care in metastatic colorectal cancer.转移性结直肠癌的治疗相关毒性及支持治疗
J Support Oncol. 2010 Jan-Feb;8(1):15-20.
2
Inhibition of transcription by platinum antitumor compounds.铂类抗肿瘤化合物对转录的抑制作用。
Metallomics. 2009;1(4):280-91. doi: 10.1039/b907567d.
3
Paclitaxel plus oxaliplatin for recurrent or metastatic cervical cancer: a New York Cancer Consortium Study.紫杉醇联合奥沙利铂治疗复发或转移性宫颈癌：纽约癌症联盟研究
Gynecol Oncol. 2010 Mar;116(3):442-6. doi: 10.1016/j.ygyno.2009.10.082. Epub 2009 Nov 20.
4
Immunogenic death of colon cancer cells treated with oxaliplatin.奥沙利铂处理的结肠癌细胞的免疫原性死亡。
Oncogene. 2010 Jan 28;29(4):482-91. doi: 10.1038/onc.2009.356. Epub 2009 Nov 2.
5
Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial.在MOSAIC试验中，奥沙利铂、氟尿嘧啶和亚叶酸作为II期或III期结肠癌辅助治疗可提高总生存率。
J Clin Oncol. 2009 Jul 1;27(19):3109-16. doi: 10.1200/JCO.2008.20.6771. Epub 2009 May 18.
6
Interaction of antitumor platinum complexes with human liver microsomal cytochromes P450.抗肿瘤铂配合物与人肝微粒体细胞色素P450的相互作用。
Anticancer Drugs. 2009 Jun;20(5):305-11. doi: 10.1097/cad.0b013e328323a7a8.
7
Vinorelbine and oxaliplatin in stage IV nonsmall cell lung cancer patients unfit for cisplatin: a single-center experience.长春瑞滨与奥沙利铂用于不适宜顺铂治疗的IV期非小细胞肺癌患者：单中心经验
Anticancer Drugs. 2009 Feb;20(2):105-8. doi: 10.1097/CAD.0b013e32831cdb51.
8
Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer.转移性结直肠癌的化疗、贝伐单抗和西妥昔单抗
N Engl J Med. 2009 Feb 5;360(6):563-72. doi: 10.1056/NEJMoa0808268.
9
Mechanisms underlying chemotherapy-induced neurotoxicity and the potential for neuroprotective strategies.化疗诱导的神经毒性的潜在机制及神经保护策略的可能性。
Curr Med Chem. 2008;15(29):3081-94. doi: 10.2174/092986708786848569.
10
Long-term platinum retention after treatment with cisplatin and oxaliplatin.顺铂和奥沙利铂治疗后的长期铂潴留
BMC Clin Pharmacol. 2008 Sep 17;8:7. doi: 10.1186/1472-6904-8-7.
Zotero 插件